Soliris - a new monoclonal antibody

Alexion has launched Soliris (eculizumab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

PHARMACOLOGY
Eculizumab is a recombinant humanised monoclonal antibody. It prevents complement-mediated lysis of PNH red blood cells which are abnormally sensitive to destruction.

Eculizumab achieves this by specifically binding to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.

This results in decreased haemolysis, decreased transfusions and a reduction in occurrence of thrombosis in PNH patients.

 

Further information: Alexion 01483 246641


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases